Abstract
A calcium channel blocker (CCB), azelnidipine (AZ), is reported to inhibit oxidative stresses, particularly when administered under blockade of the renin-angiotensin system (RAS). The purpose of this study was to investigate whether AZ inhibits oxidative stresses more potently than other CCBs under blockade of RAS and exerts renoprotection in type 2 diabetic nephropathy. Subjects were hypertensive type 2 diabetics with nephropathy, taking RAS inhibitors. The patients were randomly assigned to two groups, an AZ group (n=21, 16 mg/d) and a nifedipine-CR (NF) group (n=17, 40 mg/d). The plasma levels of monocyte chemoattractant protein-1 (MCP-1), interleukin-6 (IL-6), high-sensitive C-reactive protein (hsCRP), adiponectin and tumor necrosis factor-α (TNFα), the urinary excretion of 8-epi-prostaglandin F2α (8-epi-PGF2α) and 8-hydroxydeoxyguanosine (8-OHdG), and the urinary albumin-to-creatinine ratios (ACR) were determined before and after 16-week treatment. Neither metabolic parameters nor blood pressure levels differed between the two groups not only at baseline but also after the treatment. However, significant decreases in MCP-1, IL-6, hsCRP, TNFα, 8-epi-PGF2α, 8-OHdG and ACR levels, and a significant increase in the plasma adiponectin level were detected in the AZ group, but not in the NF group. The % change in the urinary oxidative stress markers correlated with that in ACR. Our results indicate that, in hypertensive patients with diabetic nephropathy, a combination therapy of RAS inhibitors and AZ is an effective therapeutic modality for decreasing not only blood pressure but also inflammations and oxidative stresses.
Similar content being viewed by others
Article PDF
References
Brownlee M : Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414: 813–820.
Sheetz MJ, King GL : Molecular understanding of hyperglycemia’s adverse effects for diabetic complications. JAMA 2002; 288: 2579–2588.
Taniyama Y, Griendling KK : Reactive oxygen species in the vasculature: molecular and cellular mechanisms. Hypertension 2003; 42: 1075–1081.
Viberti G, Wheeldon NM, MicroAlbuminuria Reduction with VALsartan (MARVAL) Study Investigators : Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002; 106: 672–678.
Ogawa S, Mori T, Nako K, et al: Angiotensin II type 1 receptor blockers reduce urinary oxidative stress markers in hypertensive diabetic nephropathy. Hypertension 2006; 47: 699–705.
Yamagishi T : Efficacy of azelnidipine on home blood pressure and pulse rate in patients with essential hypertension: comparison with amlodipine. Hypertens Res 2006; 29: 767–773.
Nakamura T, Sugaya T, Kawagoe Y, et al: Azeinidipine reduces urinary protein excretion and urinary liver-type fatty acid binding protein in patients with hypertensive chronic kidney disease. Am J Med Sci 2007; 333: 321–326.
Shinomiya K, Mizushige K, Fukunaga M, et al: Antioxidant effect of a new calcium antagonist, azelnidipine, in cultured human arterial endothelial cells. J Int Med Res 2004; 32: 170–175.
Yamagishi S, Inagaki Y, Nakamura K, et al: Azelnidipine, a newly developed long-acting calcium antagonist, inhibits tumor necrosis factor-alpha-induced interleukin-8 expression in endothelial cells through its anti-oxidative properties. J Cardiovasc Pharmacol 2004; 43: 724–730.
Matsui T, Yamagishi S, Nakamura K, et al: Azelnidipine, a dihydropyridine-based calcium antagonist, inhibits angiotensin II-induced oxidative stress generation and downregulation of pigment epithelium-derived factor mRNA levels in microvascular endothelial cells. Drugs Exp Clin Res 2005; 3: 215–219.
Jinno T, Iwai M, Li Z, et al: Calcium channel blocker azelnidipine enhances vascular protective effects of AT1 receptor blocker olmesartan. Hypertension 2004; 43: 263–269.
Manabe S, Okura T, Fukuoka T, et al: Antioxidative effects of azelnidipine on mesangial cell proliferation induced by highly concentrated insulin. Eur J Pharmacol 2007: 567: 252–257.
Kim-Mitsuyama S, Izumi Y, Izumiya Y, et al: Additive beneficial effects of the combination of a calcium channel blocker and an angiotensin blocker on a hypertensive rat-heart failure model. Hypertens Res 2004; 27: 771–779.
Imai E, Horio M, Nitta K, et al: Modification of the MDRD Study equation for Japan. Am J Kidney Dis 2007; 50: 927–937.
Matsui T, Yamagishi S, Nakamura K, Inoue H : Azelnidipine, a new long-acting calcium-channel blocker, inhibits tumor necrosis factor-α-induced monocyte chemoattractant protein-1 expression in endothelial cells. J Int Med Res 2006; 34: 671–675.
Nakamura K, Yamagishi S, Inoue H : Unique atheroprotective property of azelnidipine, a dihydropyridine-based calcium antagonist. Med Hypotheses 2005; 65: 155–157.
Suzuki J, Iwai M, Li Z, et al: Effect of combination of calcium antagonist, azelnidipine, and AT1 receptor blocker, olmesartan, on atherosclerosis in apolipoprotein E-deficient mice. J Hypertens 2005; 23: 1383–1389.
Iwai M, Chen R, Ide A, et al: The calcium-channel blocker, azelnidipine, enhances the inhibitory action of AT1 receptor blockade on ischemic brain damage. J Hypertens 2006; 24: 2023–2031.
Yamagishi S, Takeuchi M, Inoue H : Renoprotective effects of azelnidipine, a dihydropyridine-based calcium antagonist in advanced glycation end product (AGE)-injected rats. Int J Tissue React 2005; 27: 1337–1343.
Koike H, Kimura T, Kawasaki T, et al: Azelnidipine, a long-acting calcium channel blocker with slow onset and high vascular affinity. Annu Rep Sankyo Res Lab 2002: 54: 1–64.
Koyama Y, Takeishi Y, Takahashi H, et al: Azelnidipine inhibits H2O2-induced cell death in neonatal rat cardiomyocytes. Cardiovasc Drugs Ther 2007; 21: 69–72.
Naito Y, Shimozawa M, Manabe H, et al: Azelnidipine, a new calcium channel blocker, inhibits endothelial inflammatory response by reducing intracellular levels of reactive oxygen species. Eur J Pharmacol 2006; 546: 11–18.
Kurata A, Nishizawa H, Kihara S, et al: Blockade of angiotensin II type-1 receptor reduces oxidative stress in adipose tissue and ameliorates adipocytokine dysregulation. Kidney Int 2006; 70: 1717–1724.
Furuhashi M, Ura N, Higashiura K, et al: Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 2003; 42: 76–81.
Gustafson B, Hammarstedt A, Andersson CX, et al: Inflamed adipose tissue: a culprit underlying the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 2007; 27: 2276–2283.
Ailhaud G : Adipose tissue as a secretory organ: from adipogenesis to the metabolic syndrome. C R Biol 2006; 329: 570–577.
Coenen KR, Gruen ML, Chait A, et al: Diet-induced increases in adiposity, but not plasma lipids, promote macrophage infiltration into white adipose tissue. Diabetes 2007; 56: 564–573.
Piecha G, Adamczak M, Chudek J, et al: Indapamide decreases plasma adiponectin concentration in patients with essential hypertension. Kidney Blood Press Res 2007; 30: 187–194.
Watanabe S, Okura T, Kurata M, et al: The effect of losartan and amlodipine on serum adiponectin in Japanease adults with essential hypertension. Clin Ther 2006; 28: 1677–1685.
Nomura S, Inami N, Kimura Y, et al: Effect of nifedipine on adiponectin in hypertensive patients with type 2 diabetes mellitus. J Hum Hypertens 2007; 21: 38–44.
Yilmaz MI, Sonmez A, Caglar K, et al: Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome. Nephrology (Carlton) 2007; 12: 1447–1453.
Kamei N, Tobe K, Suzuki R, et al: Overexpression of monocyte chemoattractant protein-1 in adipose tissues causes macrophage recruitment and insulin resistance. J Biol Chem 2006; 281: 26602–26614.
Kang L, Sebastian BM, Pritchard MT, Pratt BT, Previs SF, Nagy LE : Chronic ethanol-induced insulin resistance is associated with macrophage infiltration into adipose tissue and altered expression of adipocytokines. Alcohol Clin Exp Res 2007; 31: 1581–1588.
Woo HM, Kang JH, Kawada T, et al: Active spice-derived components can inhibit inflammatory responses of adipose tissue in obesity by suppressing inflammatory actions of macrophages and release of monocyte chemoattractant protein-1 from adipocytes. Life Sci 2007; 80: 926–931.
Yagil Y, Miyamoto M, Frasier L, et al: Effects of CS-905, a novel dihydropyridine calcium channel blocker, on arterial pressure, renal excretory function, and inner medullary blood flow in the rat. Am J Hypertens 1994; 7: 637–646.
Kanazawa M, Kohzuki M, Yoshida K, et al: Combination therapy with an angiotensin-converting enzyme (ACE) inhibitor and a calcium antagonist: beyond the renoprotective effects of ACE inhibitor monotherapy in a spontaneous hypertensive rat with renal ablation. Hypertens Res 2002; 25: 447–453.
Tanaka T, Nangaku M, Miyata T, et al: Blockade of calcium influx through L-type calcium channels attenuates mitochondrial injury and apoptosis in hypoxic renal tubular cells. J Am Soc Nephrol 2004; 15: 2320–2333.
Kondo N, Kiyomoto H, Yamamoto T, et al: Effects of calcium channel blockade on angiotensin II-induced peritubular ischemia in rats. J Pharmacol Exp Ther 2006; 316: 1047–1052.
Ogawa S, Takeuchi K, Mori T, et al: Effects of monotherapy of temocapril or candesartan with dose increments or combination therapy with both drugs on the suppression of diabetic nephropathy. Hypertens Res 2007; 30: 325–334.
Nielsen FS, Hansen HP, Jacobsen P, et al: Increased sympathetic activity during sleep and nocturnal hypertension in Type 2 diabetic patients with diabetic nephropathy. Diabet Med 1999; 16: 555–562.
Perin PC, Maule S, Quadri R : Sympathetic nervous system, diabetes, and hypertension. Clin Exp Hypertens 2001; 23: 45–55.
Scholz H : Pharmacological aspects of calcium channel blockers. Cardiovasc Drugs Ther 1997; 10: 869–872.
Damase-Michel C, Valet P, Montastruc JL : Nicardipine causes sympathetic activation that does not involve baroreceptor reflex tachycardia in conscious sinoaortic-denervated dogs. Eur J Pharmacol 1987; 142: 145–149.
Shokoji T, Fujisawa Y, Kiyomoto H, et al: Effects of a new calcium channel blocker, azelnidipine, on systemic hemodynamics and renal sympathetic nerve activity in spontaneously hypertensive rats. Hypertens Res 2005; 28: 1017–1023.
Kimura Y, Hirooka Y, Sagara Y, et al: Long-acting calcium channel blocker, azelnidipine, increases endothelial nitric oxide synthase in the brain and inhibits sympathetic nerve activity. Clin Exp Hypertens 2007; 29: 13–21.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ogawa, S., Mori, T., Nako, K. et al. Combination Therapy with Renin-Angiotensin System Inhibitors and the Calcium Channel Blocker Azelnidipine Decreases Plasma Inflammatory Markers and Urinary Oxidative Stress Markers in Patients with Diabetic Nephropathy. Hypertens Res 31, 1147–1155 (2008). https://doi.org/10.1291/hypres.31.1147
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1291/hypres.31.1147
Keywords
This article is cited by
-
Therapeutic Usefulness of a Novel Calcium Channel Blocker Azelnidipine in the Treatment of Hypertension: A Narrative Review
Cardiology and Therapy (2022)
-
Potential Protective Role of Blood Pressure-Lowering Drugs on the Balance between Hemostasis and Fibrinolysis in Hypertensive Patients at Rest and During Exercise
American Journal of Cardiovascular Drugs (2019)
-
Azelnidipine, but not amlodipine, reduces urinary albumin excretion and carotid atherosclerosis in subjects with type 2 diabetes: blood pressure control with olmesartan and azelnidipine in Type 2 diabetes (BOAT2 study)
Diabetology & Metabolic Syndrome (2015)
-
Effect of N- and T-type calcium channel blocker on proteinuria, blood pressure and kidney function in hypertensive patients: a meta-analysis
Hypertension Research (2015)
-
Chapter 6. Hypertension associated with organ damage
Hypertension Research (2014)